Jaguar Health(JAGX) - 2024 Q2 - Quarterly Report

Financial Performance - Jaguar Health, Inc. reported a net loss of $19.0 million for the six months ended June 30, 2024, compared to a net loss of$24.7 million for the same period in 2023[257]. - The company reported a net loss of $18.996 million for the six months ended June 30, 2024, a 23.1$24.688 million in the same period of 2023[270]. - Net loss attributable to common stockholders decreased by $2.658 million from$12.150 million for the three months ended June 30, 2023, to $9.492 million in 2024[289]. - Net cash used in operating activities for the six months ended June 30, 2024, was$15.2 million, compared to $19.0 million for the same period in 2023[309]. Revenue and Sales - Product revenue for the six months ended June 30, 2024, was$5.072 million, a 9.1% increase from $4.648 million in the same period of 2023[270]. - Gross product sales increased to$7.045 million for the six months ended June 30, 2024, compared to $6.304 million in 2023, reflecting an 11.8$2.721 million, an increase of $45,000 or 1.7$2.676 million in the same period in 2023[289]. Expenses - Research and development expenses are expected to increase due to the start-up costs associated with clinical trials for new indications[262]. - Research and development expenses decreased by $1.087 million, or 12.0$9.052 million in the six months ended June 30, 2023, to $7.965 million in 2024[278]. - Sales and marketing expenses decreased by$490,000, or 14.2%, from $3.457 million in the six months ended June 30, 2023, to$2.967 million in 2024[280]. - Total operating expenses for the three months ended June 30, 2024, were $9.918 million, a decrease of$860,000 or 8.0% compared to $10.778 million in the same period in 2023[289]. - General and administrative expenses decreased by$555,000 from $9.25 million for the six months ended June 30, 2023, to$8.7 million in the same period in 2024, primarily due to a $308,000 decrease in personnel and related benefits[282]. Debt and Financing - Gain on extinguishment of debt was$1.245 million for the six months ended June 30, 2024, compared to no gain in the same period of 2023[270]. - Gain on extinguishment of debt increased by $1.2 million from zero in the six months ended June 30, 2023, to$1.2 million for the same period in 2024[287]. - Cash provided by financing activities increased to $24.8 million in the six months ended June 30, 2024, from$22.2 million in the same period in 2023[313]. Market and Product Development - The global market for Short Bowel Syndrome (SBS) is projected to exceed $4.6 billion by 2027, with approximately 10,000 to 20,000 people affected in the U.S.[249]. - Jaguar plans to launch Gelclair, an FDA-approved oral mucositis prescription product, in the fourth quarter of 2024, which addresses a common side effect of cancer treatment[244]. - Crofelemer, Jaguar's lead product, is in development for multiple indications, including chemotherapy-induced diarrhea (CID) and diarrhea-predominant irritable bowel syndrome (IBS-D)[251]. - The company has initiated clinical development of crofelemer for SBS patients, leveraging the EMA's accelerated conditional marketing authorization pathway[249]. - Jaguar's joint venture, Magdalena, focuses on developing plant-based medicines for mental health, including ADHD, utilizing a library of 2,300 medicinal plants[253]. - Canalevia-CA1, an oral plant-based prescription drug for CID in dogs, has received conditional approval from the FDA and is available through multiple veterinary distributors[255]. Cost Management - Direct labor costs in the cost of product revenue decreased by$144,000, or 26.5%, from $544,000 in 2023 to$400,000 in 2024[275]. - Material costs decreased by $79,000, or 19.4$407,000 in 2023 to $328,000 in 2024, due to increased production efficiency[276]. - Interest expense decreased by$5.1 million from $5.6 million for the six months ended June 30, 2023, to$503,000 for the same period in 2024[285]. - Interest expense decreased from $3.5 million in Q2 2023 to$108,000 in Q2 2024, primarily due to changes in accounting for certain debt instruments[303]. Internal Controls and Legal Matters - As of June 30, 2024, the company concluded that its internal control over financial reporting was effective, providing reasonable assurance regarding the reliability of financial reporting in accordance with U.S. GAAP[316]. - The company is classified as a smaller reporting company and is not subject to auditor attestation requirements under applicable SEC rules[317]. - There were no changes in the internal control over financial reporting that materially affected or are likely to materially affect the internal control[317]. - The company is not currently subject to any material legal proceedings, which could have adverse effects due to defense and settlement costs[319].